Baillie Gifford & Co’s RxSight RXST Stock Holding History

Baillie Gifford & Co’s Portfolio RXST Stock Details RXST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$4.25M	Sell	690,279 -2,867	-0.4%	-$23.8K	﹤0.01%	240
2025 Q4	$7.22M	Buy	693,146 +6,830	+1%	+$68.5K	0.01%	228
2025 Q3	$6.17M	Buy	686,316 +217,371	+46%	+$1.91M	﹤0.01%	233
2025 Q2	$6.1M	Buy	468,945 +76,714	+20%	+$1.15M	﹤0.01%	223
2025 Q1	$9.9M	Sell	392,231 -6,676	-2%	-$198K	0.01%	211
2024 Q4	$13.7M	Sell	398,907 -20,097	-5%	-$906K	0.01%	200
2024 Q3	$20.7M	Buy	419,004 +60,789	+17%	+$3.11M	0.02%	179
2024 Q2	$21.6M	Buy	358,215 +291,733	+439%	+$16.7M	0.02%	178
2024 Q1	$3.43M	Buy	+66,482	New	+$3.26M	﹤0.01%	244

Other funds holding RXST

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Nomura Holdings Tokyo, Japan $37.7B AUM 34.44% 1-Year Est. Return

NSGL

No Street GP LP San Francisco, California $1.5B AUM 34.53% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

Baillie Gifford & Co's RXST Position: Q1 2026 in Review

Baillie Gifford & Co reduced its RxSight (RXST) stake by 0.41% in Q1 2026, selling an estimated $23.8K and leaving 690,279 shares worth $4.25M. The position accounts for ﹤0.01% of the portfolio, ranked #240.

Baillie Gifford & Co first reported a position in RXST in Q1 2024 and has held it in 9 quarters since. The position peaked at $21.6M in Q2 2024. 164 funds tracked by Wall St. Rank hold RXST as of Q1 2026.

Baillie Gifford & Co held 690,279 shares of RxSight worth $4.25M as of Q1 2026.
Baillie Gifford & Co sold 2,867 RxSight shares in Q1 2026, an estimated $23.8K.
RxSight made up ﹤0.01% of Baillie Gifford & Co's portfolio in Q1 2026, its #240 holding.
Baillie Gifford & Co first reported a position in RxSight in Q1 2024 and has held it in 9 quarters since.
Baillie Gifford & Co's RxSight position peaked at $21.6M in Q2 2024.
164 funds tracked by Wall St. Rank held RxSight as of Q1 2026.

Based on Baillie Gifford & Co's 13F filing for Q1 2026, filed 8 May 2026.